Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine—A Prospective Cohort Study by the AGMT-Reference-Cited by-同舟云学术

Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine—A Prospective Cohort Study by the AGMT

Published:2023-02-22 Issue:5 Volume:15 Page:1388
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Pleyer Lisa¹²³,Heibl Sonja¹⁴,Tinchon Christoph¹⁵,Vallet Sonia¹⁶,Schreder Martin¹⁷^ORCID,Melchardt Thomas¹²³,Stute Norbert¹²³,Föhrenbach Quiroz Kim Tamara²,Leisch Michael¹²³,Egle Alexander¹²³,Scagnetti Lukas¹⁴,Wolf Dominik¹⁸,Beswick Richard⁹,Drost Manuel¹⁰,Larcher-Senn Julian¹⁰^ORCID,Grochtdreis Thomas¹¹^ORCID,Vaisband Marc¹²¹²,Hasenauer Jan¹²,Zaborsky Nadja²³¹³^ORCID,Greil Richard¹²³^ORCID,Stauder Reinhard¹⁸^ORCID

Affiliation:

1. Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria

2. Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria

3. 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, Austria

4. 4th Medical Department of Internal Medicine, Hematology, Internistic Oncology and Palliative Medicine, Klinikum Wels-Grieskirchen GmbH, 4600 Wels, Austria

5. Department for Hemato-Oncology, LKH Hochsteiermark, 8700 Leoben, Austria

6. Department of Internal Medicine 2, University Hospital Krems, Karl Landsteiner Private University of Health Sciences, 3500 Krems, Austria

7. 1st Department of Internal Medicine, Center for Oncology and Hematology, Klinik Ottakring, Wiener Gesundheitsverbund, 1030 Vienna, Austria

8. Department of Internal Medicine V, Innsbruck Medical University, 6020 Innsbruck, Austria

9. International Marketing, Swiss Business School, 8302 Zurich, Switzerland

10. Assign Data Management and Biostatistics GmbH, 6020 Innsbruck, Austria

11. Department of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany

12. Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany

13. Laboratory of Immunological and Molecular Cancer Research (LIMCR), 5020 Salzburg, Austria

Abstract

In this prospective study (NCT01595295), 272 patients treated with azacitidine completed 1456 EuroQol 5-Dimension (EQ-5D) questionnaires. Linear mixed-effect modelling was used to incorporate longitudinal data. When compared with a matched reference population, myeloid patients reported more pronounced restrictions in usual activities (+28%, p < 0.0001), anxiety/depression (+21%, p < 0.0001), selfcare (+18%, p < 0.0001) and mobility (+15%, p < 0.0001), as well as lower mean EQ-5D-5L indices (0.81 vs. 0.88, p < 0.0001), and lower self-rated health on the EuroQol Visual Analogue Scale (EQ-VAS) (64 vs. 72%, p < 0.0001). After multivariate-adjustment, (i) the EQ-5D-5L index assessed at azacitidine start the predicted time with clinical benefit (TCB) (9.6 vs. 6.6 months; p = 0.0258; HR = 1.43), time to next treatment (TTNT) (12.8 vs. 9.8 months; p = 0.0332; HR = 1.42) and overall survival (OS) (17.9 vs. 12.9 months; p = 0.0143; HR = 1.52); (ii) Level Sum Score (LSS) predicted azacitidine response (p = 0.0160; OR = 0.451) and the EQ-5D-5L index showed a trend (p = 0.0627; OR = 0.522); (iii) up to 1432 longitudinally assessed EQ-5D-5L response/clinical parameter pairs revealed significant associations of EQ-5D-5L response parameters with haemoglobin level, transfusion dependence and hematologic improvement. Significant increases of the likelihood ratios were observed after addition of LSS, EQ-VAS or EQ-5D-5L-index to the International Prognostic Scoring System (IPSS) or the revised IPSS (R-IPSS), indicating that they provide added value to these scores.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/5/1388/pdf

Reference64 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study;Fenaux;Lancet Oncol.,2009

2. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B;Silverman;J. Clin. Oncol.,2002

3. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: A retrospective cohort study;Pleyer;Lancet Haematol.,2021

4. FDA (2022, June 01). Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Available online: https://www.fda.gov/media/77832/download.

5. FDA (2022, June 01). Core Patient-Reported Outcomes in Cancer Clinical Trials Guidance for Industry—Draft Guidance, Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/core-patient-reported-outcomes-cancer-clinical-trials.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transfusion avoidance in myelodysplastic neoplasms;Current Opinion in Hematology;2023-11-16

2. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT;American Journal of Hematology;2023-08-07